Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass

Medical Principles and Practice

Volumn 21, Issue 1, 2011, Pages 30-35

  Gong, Ming ^a   Lin, Xue Zheng ^b   Lu, Guang Tao ^b   Zheng, Li Juan ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b TAIZHOU CENTRAL HOSPITAL   (China)

Author keywords

Cardiac surgery; Inflammation; Milrinone inhalation

Indexed keywords

GELATINASE B; INTERLEUKIN 6; MILRINONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART HEMODYNAMICS; HEART SURGERY; HUMAN; INFLAMMATION; MALE; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT;

ADMINISTRATION, INHALATION; ANALYSIS OF VARIANCE; CARDIOPULMONARY BYPASS; CYTOKINES; FEMALE; HEMODYNAMICS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MILRINONE; PHOSPHODIESTERASE 3 INHIBITORS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955187770     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000332411     Document Type: Article

References (29)

1. Suleiman MS, Zacharowski K, Angelini GD: Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmacol 2008; 153: 21-33.
2. Taylor KM: SIRS - the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1607-1608. (Pubitemid 26179703)
3. Raja SG, Dreyfus GD: Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann 2005; 13: 382-395. (Pubitemid 41824742)
4. Moore AR, Willoughby DA: The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995; 101: 387-389.
5. Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, Shearer GM: Modulation of inflammation and immunity by cyclic AMP. Science 1974; 184: 19-28.
6. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520. (Pubitemid 44394910)
7. Lehtonen LA, Antila S, Pentikäinen PJ: Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004; 43: 187-203. (Pubitemid 38293791)
8. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Kawara T, Aoyagi S: Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999; 68: 1661-1667.
9. Blease K, Burke-Gaffney A, Hellewell PG: Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998; 124: 229-237. (Pubitemid 28210064)
10. Irie K, Fujii E, Ishida H, Wada K, Suganuma T, Nishikori T, Yoshioka T, Muraki T: Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br J Pharmacol 2001; 133: 237-242. (Pubitemid 32507042)
11. Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, Ito Y: Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 2006; 26: 522-526. (Pubitemid 44632284)
12. Levy JH, Bailey JM, Deeb GM: Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002; 73: 325-330. (Pubitemid 34084602)
13. Wang H, Gong M, Zhou B, Dai A: Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26: 462-468.
14. Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A: Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161-165. (Pubitemid 20218956)
15. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829-1835. (Pubitemid 23097351)
16. Asimakopoulos G: Systemic inflammation and cardiac surgery: an update. Perfusion 2001; 16: 353-360. (Pubitemid 32834429)
17. Bergman MR, Holycross BJ: Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996; 279: 247-254. (Pubitemid 27166918)
18. Schlensak C, Doenst T, Preusser S, Wunderlich M, Kleinschmidt M, Beyersdorf F: Cardiopulmonary bypass reduction of bronchial blood flow: a potential mechanism for lung injury in a neonatal pig model. J Thorac Cardiovasc Surg 2002; 123: 1199-1205.
19. Schlensak C, Doenst T, Preusser S, Wunderlich M, Kleinschmidt M, Beyersdorf F: Bronchial artery perfusion during cardiopulmonary bypass does not prevent ischemia of the lung in piglets: assessment of bronchial artery blood flow with fluorescent microspheres. Eur J Cardiothorac Surg 2001; 19: 326-331.
20. Lamarche Y, Malo O, Thorin E, Denault A, Carrier M, Roy J, Perrault LP: Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 83-92. (Pubitemid 40941673)
21. Chen F, Nakamura T, Fujinaga T, Zhang J, Hamakawa H, Omasa M, Sakai H, Hanaoka N, Bando T, Wada H, Fukuse T: Protective effect of a nebulized beta 2 -adrenoreceptor agonist in warm ischemic-reperfused rat lungs. Ann Thorac Surg 2006; 82: 465-471. (Pubitemid 44080011)
22. Hoffmann SC, Bleiweis MS, Jones DR, Paik HC, Ciriaco P, Egan TM: Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury. Am J Respir Crit Care Med 2001; 163: 1642-1647. (Pubitemid 32578770)
23. Bueltmann M, Kong X, Mertens M, Yin N, Yin J, Liu Z, Koster A, Kuppe H, Kuebler WM: Inhaled milrinone attenuates experimental acute lung injury. Intensive Care Med 2009; 35: 171-178.
24. Emonard H, Grimaud JA: Matrix metalloproteinases: a review. Cell Mol Biol 1990; 36: 131-153.
25. Johnson LL, Dyer R, Hupe DJ: Matrix metalloproteinases. Curr Opin Chem Biol 1998; 2: 466-471. (Pubitemid 128645699)
26. Lin TC, Li CY, Tsai CS, Ku CH, Wu CT, Wong CS, Ho ST: Neutrophil-mediated secretion and activation of matrix metalloproteinase- 9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg 2005; 100: 1554-1560.
27. Steinberg J, Fink G, Picone A, Searles B, Schiller H, Lee HM, Nieman G: Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass. J Extra Corpor Technol 2001; 33: 218-222. (Pubitemid 34142989)
28. Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, Johnson KJ, Varani J: Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 2006; 37: 422-430.
29. Kim JH, Suk MH, Yoon DW, Lee SH, Hur GY, Jung KH, Jeong HC, Lee SY, Lee SY, Suh IB, Shin C, Shim JJ, In KH, Yoo SH, Kang KH: Inhibition of matrix metalloproteinase- 9 prevents neutrophilic inflammation in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291:L580-L587. (Pubitemid 44498467)